1.
Antimicrob Agents Chemother
; 57(2): 1101-2, 2013 Feb.
Article
in English
| MEDLINE
| ID: mdl-23229478
Subject(s)
Bacterial Proteins/genetics , Klebsiella Infections/microbiology , Klebsiella pneumoniae/drug effects , Klebsiella pneumoniae/genetics , Pneumonia, Bacterial/microbiology , beta-Lactamases/genetics , Aged , Anti-Bacterial Agents/therapeutic use , Colombia , Cross Infection/drug therapy , Cross Infection/microbiology , Female , Humans , Klebsiella Infections/drug therapy , Klebsiella pneumoniae/enzymology , Klebsiella pneumoniae/isolation & purification , Meropenem , Pneumonia, Bacterial/drug therapy , Stroke , Thienamycins/therapeutic use
2.
Antimicrob Agents Chemother
; 56(10): 5422-3, 2012 Oct.
Article
in English
| MEDLINE
| ID: mdl-22825120
3.
Clin Microbiol Infect
; 17(1): 52-6, 2011 Jan.
Article
in English
| MEDLINE
| ID: mdl-20219078
ABSTRACT
In 2008, an increase in the prevalence of carbapenem-resistant Klebsiella pneumoniae was noted in a 286-bed tertiary case hospital in Colombia, where 84 patients (32 infected and 52 colonized) had positive cultures. The identified index patient came from Israel for a liver transplantation. High level carbapenem resistance was observed. Polymyxin B and tigecycline were the only two antibiotics that remained active. PCR-restriction fragment length polymorphism analysis and sequencing revealed blaKPC-3 in the major clone, which was indistinguishable from the K. pneumoniae carbapenemase-3-producing clone described previously in Israel. This exemplifies the threat posed by the global spread of K. pneumoniae carbapenemase-producing pathogens.